• Skye Bioscience investor deck highlighted clinical combination data for obesity program pairing peripheral CB1 antibody nimacimab with semaglutide.
• CBeyond readout showed 3% incremental weight loss versus semaglutide alone at 26 weeks.
• Mean weight loss reached 22.3% at 52 weeks, with no plateau observed.
• Safety summary cited no nimacimab-associated neuropsychiatric signal through 52 weeks, with no additive gastrointestinal burden versus semaglutide.
• Development update flagged 200 mg weekly nimacimab monotherapy as underexposed in peripheral tissues, with a higher-dose expansion study under way to increase exposure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.